Cytomegalovirus infection complicating immunosuppressive therapy for dermatomyositis.
The occurrence of opportunistic infections is not rare during the treatment of connective tissue diseases, including dermatomyositis because of the patient's immunosuppression. We describe here cytomegalovirus (CMV) infection that affected two of our patients with dermatomyositis. CMV infection has not been considered to be a frequent event in dermatomyositis, and its significance for disease progression has not been sufficiently recognized. Our case reports demonstrate the importance of close monitoring of such patients and prompt initiation of appropriate therapy to manage a suspected CMV infection.
Hashimoto
Akira
A
Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Okuyama
Ryuhei
R
Watanabe
Hiroshi
H
Tagami
Hachiro
H
Aiba
Setsuya
S
D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000150:complications* / Q000188:drug therapy; D003882:Dermatomyositis / Q000150:complications* / Q000188:drug therapy; D017809:Fatal Outcome; D005260:Female; D015774:Ganciclovir / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007121:Immunocompetence; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009894:Opportunistic Infections / Q000150:complications* / Q000188:drug therapy; D011239:Prednisolone / Q000627:therapeutic use
D000998:Antiviral Agents; D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011239:Prednisolone; D015774:Ganciclovir